Black Rock Inc. Aridis Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.31 - $1.5 $3,921 - $18,976	-12,651 Reduced 73.28%	4,612 $1,000
Q4 2022 Feb 13, 2023	SELL	$0.81 - $1.18 $149 - $218	-185 Reduced 1.06%	17,263 $20,000
Q3 2022 Nov 14, 2022	SELL	$0.73 - $2.47 $209 - $708	-287 Reduced 1.62%	17,448 $16,000
Q2 2022 Aug 12, 2022	SELL	$0.91 - $1.7 $16,462 - $30,754	-18,091 Reduced 50.5%	17,735 $20,000
Q1 2022 May 12, 2022	SELL	$1.33 - $2.59 $9,808 - $19,101	-7,375 Reduced 17.07%	35,826 $63,000
Q4 2021 Feb 10, 2022	BUY	$2.0 - $3.65 $1,948 - $3,555	974 Added 2.31%	43,201 $101,000
Q3 2021 Nov 09, 2021	BUY	$3.55 - $7.49 $37,679 - $79,498	10,614 Added 33.57%	42,227 $156,000
Q2 2021 Aug 11, 2021	BUY	$5.3 - $7.4 $167,548 - $233,936	31,613 New	31,613 $234,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.